This Market-Beating Stock Just Gave Investors More Reasons to Invest
Investing wisdom tells us to buy low, but what exactly constitutes a "low" point? Consider the case of Regeneron (NASDAQ: REGN), a biotech company that has beaten the market in recent years. Despite its doing so, one could argue that the drugmaker, which isn't that far off from its 52-week high, is still worth buying at current levels, given the company's prospects and upside potential.
Let's discuss recent developments with Regeneron and determine why the company's shares are still worth buying.
Source Fool.com
Regeneron Pharmaceuticals Inc. Aktie
976,00 €
0,25 %
Die Community zeigt großes Interesse an Regeneron Pharmaceuticals Inc. mit vielen Buy- und wenigen Sell-Einschätzungen.
Das Kursziel von 1064 € für Regeneron Pharmaceuticals Inc. impliziert eine leichte Steigerung gegenüber dem aktuellen Kurs von 976.0 €.
